CLDI
Calidi Biotherapeutics, Inc.1.3000
-0.0300-2.26%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
9.32MP/E (TTM)
3.61Basic EPS (TTM)
0.36Dividend Yield
0%Recent Filings
8-K
New CLD-401 data at SITC
Calidi Biotherapeutics unveiled new preclinical data on RedTail platform lead CLD-401 at the SITC Annual Meeting on November 7, 2025, showing tumor-specific replication, immune evasion, and high IL-15 superagonist expression in metastatic sites comparable to localized dosing—yet minimal systemic exposure. Preclinical models confirm targeted delivery. IND submission is planned by end-2026 while pursuing partnerships.
8-K
Sells Nova Cell stake
Calidi sold its entire 75% stake in Nova Cell for $6M on October 27, 2025—$1.2M via debt cancellation, $4.8M deferred from capital raises and royalties—while transferring cell materials under a new purchase deal that bars oncolytic virus uses. Nova Cell exits subsidiary status. Calidi eyes $0.5M annual G&A savings.
8-K
Calidi forms expert SAB for CLD-401
Calidi Biotherapeutics announced on October 22, 2025, the formation of a Scientific Advisory Board to accelerate development of its RedTail platform and push CLD-401 into clinical trials. The board features experts like former Pfizer CMO Mace Rothenberg and virotherapy leader David Curiel, bringing deep oncology and immunotherapy know-how. This move bolsters Calidi's push for systemic genetic medicines targeting metastatic cancers. Yet risks loom in funding and trial outcomes.
8-K
Updated investor presentation released
8-K
Calidi closes $6.9M offering
Calidi Biotherapeutics closed an underwritten public offering on August 21, 2025, selling 1,922,764 common stock units and 1,528,000 pre-funded warrant units at $2.00 and $1.999 each, yielding gross proceeds of $6.9 million after full exercise of the over-allotment option. Funds will support working capital, general corporate purposes, pre-clinical studies, and clinical trial preparation amid tough market conditions. Warrants expire in five years at $2.00 exercise price. Lock-up restrictions bind insiders for 90 days.
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CALC
CalciMedica, Inc.
5.22+0.59
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CDTX
Cidara Therapeutics, Inc.
220.05-0.05
CRBU
Caribou Biosciences, Inc.
1.69-0.02
CYDY
CytoDyn Inc.
0.32+0.02
ESLA
Estrella Immunopharma, Inc.
1.63-0.18
MBIO
Mustang Bio, Inc.
1.07-0.06
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
VIR
Vir Biotechnology, Inc.
6.48-0.24